37th week of 2022 patent applcation highlights part 8 |
Patent application number | Title | Published |
20220287916 | A Teat - A teat for a milk bottle is provided. The teat comprises an attachment portion for attaching the teat to a milk bottle. A breast portion of the teat extends from the attachment portion, the breast portion including a compressible material. A nipple portion of the teat extends from the breast portion. The nipple portion is narrower than the breast portion and includes an outlet. A milk-flow pathway extends through the breast portion, the compressible material and the nipple portion for the passage of milk from a milk bottle attached to the attachment portion to the outlet. The breast portion includes a flexible skin fully enclosing the compressible material, the flexible skin separating the compressible material from the milk-flow pathway. | 2022-09-15 |
20220287917 | SYSTEM FOR DETECTING POSITION OF DISTAL END OF MEDICAL TUBE - A tube distal end position detection system ( | 2022-09-15 |
20220287918 | DENTAL ADHESIVE COMPOSITION EXCELLENT IN STORAGE STABILITY | 2022-09-15 |
20220287919 | PHOTOCURABLE COMPOSITION EXCELLENT IN CURING DEPTH | 2022-09-15 |
20220287920 | DENTAL PHOTOCURABLE COMPOSITION CONTAINING HIGH SOLUBLE PHOTOACID GENERATOR - To provide a dental photocurable composition which can exhibit excellent mechanical characteristics even after returning from a low temperature to room temperature. | 2022-09-15 |
20220287921 | DENTAL PHOTOCURABLE COMPOSITION EXCELLENT IN COLOR TONE SELECTIVITY | 2022-09-15 |
20220287922 | DENTIN REGENERATIVE CELL CULTURE - A dentin regenerative cell culture that can bring about a rapid regeneration of dentin in a deficit region. In the treatment of a tooth using the dentin regenerative cell culture, a root canal where a pulpectomy has been performed is filled with a root canal filler containing dental pulp stem cells. The dentin regenerative cell culture is then implanted in the deficit region of dentin, and temporary sealing with a packing is carried out. The dentin regenerative cell culture is formed three-dimensionally in conformity with the shape of the deficit region with the coalescence of cell masses of a plurality of odontoblasts, and thus the dentin regeneration is well promoted. In addition, gaps between the dentin regenerative cell culture and biological tissue can be rapidly filled. Infection due to bacterial infiltration can thereby be prevented. | 2022-09-15 |
20220287923 | SKIN EXTERNAL COMPOSITION - Provided is a liquid skin external composition which allows a poorly water-soluble component to be applied to a skin in a liquid state. | 2022-09-15 |
20220287924 | EMBOSSED DISPERSIBLE WET WIPES - The dispersible wet wipes of the current disclosure have sufficient strength to withstand packaging and consumer use. They also disperse sufficiently quickly to be flushable without creating potential problems for household and municipal sanitation systems. In certain instances the wipes have a first outer layer comprising a tissue web containing cellulose fibers and a plurality of embossments disposed thereon, and a second outer layer comprising a nonwoven web; a triggerable binder composition; and a wetting composition. The wipes may have a geometric mean tensile strength (GMT) greater than about 225 grams per linear inch (g/in) and a Slosh Time less than about 60 minutes. | 2022-09-15 |
20220287925 | DISPERSIBLE NONWOVEN MATERIALS INCLUDING CMC-BASED BINDERS - Nonwoven materials having at least one layer comprising cellulose fibers, synthetic fibers, or combinations thereof are provided. Such nonwoven materials are at least partially covered on their surface with a binder including carboxymethyl cellulose (CMC) and a metallic salt, the binder having a pH of from about 4.3 to about 4.5. Nonwoven materials including such binder provide for increased wet strength and dispersibility and are suitable for use in a variety of applications, including wipes. | 2022-09-15 |
20220287926 | Antiseptic Wipes - A wipe includes a cleansing composition disposed on a cloth. The cleansing composition can include an antiseptic, a humectant, an emollient, a surfactant, and a monohydric alcohol. A wipe can be made by preparing a cleansing composition and disposing the cleansing composition on a cloth. Two or more wipes may be included in a sealed package to maintain the sterile state of the wipes. A method of disinfecting skin can include applying a wipe to skin. | 2022-09-15 |
20220287927 | Systems and methods to provide towelette units. - A moistening wipe is disclosed. The wipe includes a moistening agent and a flavoring agent. The moisturizing and flavoring agents are deposited on a material. The flavoring agent imparts a pleasant taste to the surface upon which the wipe is used. | 2022-09-15 |
20220287928 | ALGINATE-BASED FACIAL MASK - The invention relates to an alginate-based facial mask, provided in the form of a water-free cosmetic composition that comprises a) at least one water-soluble alginate, b) at least one calcium salt, c) at least one oil, d) at least one emulsifier selected from the group polyglyceryl-(4) isostearate, polyglyceryl-(10) octanoate/caprate, polyglyceryl-(10) stearate, PEG-7 glyceryl cocoate, polyglyceryl-(3) methyl glucose distearate and polyglyceryl-(4) laurate. | 2022-09-15 |
20220287929 | SKIN CARE PRODUCT AND METHOD FOR ITS PRODUCTION - This invention is a skin care product and method for making same. The skin care product includes at least one capsule, the capsule comprising a matrix, one or more active ingredients incorporated or contained in the matrix, where at least the matrix has a high affinity with Reactive Oxygen Species (ROS). In an embodiment of the invention, at least one antioxidant agent is incorporated in the matrix. A capsule is a lipid particle. In an embodiment of the invention, the skin care product comprising the capsules is used for topical inhibition of Reactive Oxygen Species ROS in the skin of a person. A method for making the capsule is also disclosed. | 2022-09-15 |
20220287930 | PET CLEANING KIT - A fluid treatment kit comprises a flexible plastic container defining a first compartment and a second compartment. The first compartment contains a treating fluid. The second compartment contains at least one applicator. A breakable seal is disposed between the first compartment and the second compartment. The breakable seal is breakable to allow the treating fluid to flow into the second compartment and contact with the applicator. The applicator comprises liquid-absorbing materials and absorbs the treating fluid. The user then opens the flexible plastic container to remove the applicator and uses the applicator for the treatment of the pet. | 2022-09-15 |
20220287931 | COSMETIC COMPOSITION COMPRISING BENTONITE AS ACTIVE INGREDIENT - Provided is a cosmetic composition comprising bentonite as an active ingredient. The cosmetic composition according to the present disclosure reduces the expression of inflammatory mechanism proteins and inflammatory mechanism genes in keratinocytes and hypodermal cells, exhibits an anti-inflammatory function, increases the moisture content of the skin, reduces redness in the skin, and increases the brightness of the skin, thereby being effective in skin whitening and skin moisturizing. | 2022-09-15 |
20220287932 | TOPICAL COSMETIC COMPOSITION, USE OF THE COSMETIC COMPOSITION AND MASK FOR FACIAL APPLICATION - The present invention refers to a topical cosmetic composition that provides immediate and prolonged reduction and control of skin oiliness, as well as pore size reduction, reduction of skin shine and visual imperfections. The composition further maintains the skin's natural and healthy microbiota. The present invention is within the field of cosmetic science, more precisely it concerns skin care preparations. | 2022-09-15 |
20220287933 | DEPOSITION SYSTEM FOR HAIR - A hair treatment composition comprising: a) a conditioning base comprising: i) a cationic conditioning surfactant having from 16 to 32 carbon atoms; ii) a fatty alcohol having from 8 to 22 carbon atoms; and b) from 0.1 to 10 wt % of metal pyrithiones and mixtures thereof; wherein the composition further comprises: (c) from 0.1 to 5 wt % of a diesterquat; and wherein the ratio of b) to c) is from 1:1 to 1:0.1, provides improved deposition of metal pyrithione on hair surfaces. | 2022-09-15 |
20220287934 | COMPOSITION FOR EXTERNAL APPLICATION - A topical composition comprises (A) at least one polyhydric alcohol having a molecular weight of 100 to 200, and (B) at least one non-polymerizable cationic compound. The component (B) may be a compound containing a metal to be a divalent or higher cation in an aqueous solution, a basic amino acid, alkanol amine, or alkyl amine, and the component (A) may be glucose, sorbitol, fructose, xylitol, or erythritol. | 2022-09-15 |
20220287935 | CANNABINOID-CONTAINING SKIN CARE COMPOSITIONS - Cosmetic or cosmeceutical formulations comprising cannabidiol (CBD), cannabigerol (CBG) and pomegranate seed oil (PSO), products containing same and uses thereof are provided. | 2022-09-15 |
20220287936 | AN ANTIDANDRUFF COMPOSITION - Disclosed is an antidandruff composition comprising synergistic combination of itaconic acid or an ester thereof and a benzoic acid or a salt thereof in specific ratio ranges. The composition may be used for personal cleansing and is especially preferred to be delivered as a shampoo or hair conditioner. | 2022-09-15 |
20220287937 | SKIN SERUM AND PROCESS OF MAKING THE SAME - An anti-aging serum to slow the aging process by providing fuel to skin cells through topical application of a precursor Krebs cycle intermediate and associated fuel to dampen the effects of aging brought on by cellular replication and metabolism related irregularities. The serum improves skin experiencing mild to moderate wrinkling and mild to moderate mottled hyperpigmentation helping to achieve a more youthful look. | 2022-09-15 |
20220287938 | COSMETIC COMPOSITION COMPRISING EUTECTIC MIXTURE - The present invention relates to a cosmetic composition comprising a eutectic mixture containing: an amino acid, an alpha-hydroxy acid, and water; or two types of amino acids. The cosmetic comprises either an amino acid and an alpha-hydroxy acid or two types of amino acids in the form of a eutectic mixture. Thus, a cosmetic composition with excellent skin penetration effect even under weakly acidic or neutral pH conditions, which causes less irritation, can be provided, wherein the cosmetic composition provides excellent keratin exfoliation, reduces the number of pores, enhances skin elasticity, and promotes skin regeneration while having excellent low-temperature stability. | 2022-09-15 |
20220287939 | AGENT FOR MODIFYING PIGMENT TO DYE, AND COLORANT COMPOSITION COMPRISING THE DYE - The present specification discloses a agent composition for modifying a pigment to dye that imparts tinting strength to the pigment, and a colorant composition in which a pigment is modified to dye using the same. According to the present disclosure, since the pigment has tinting strength on the skin, it is possible to realize various colors of the pigment as it is while having excellent durability when applied to the skin. Accordingly, the pigment may be comprised as a coloring agent in a cosmetic formulation requiring coloring by replacing the dye having a limitation in type and color when used in a cosmetic composition due to a stability problem for the skin. In addition, since the coloring agent according to the present disclosure has an irreversibly stabilized form, it can be widely used without being limited to the pH, formulation, etc. of the cosmetic composition. | 2022-09-15 |
20220287940 | Oral Care Composition Comprising Rottlerin - An oral care composition including rottlerin in an amount sufficient to reduce a growth of gram-positive bacteria in a mouth treated with the oral care composition. | 2022-09-15 |
20220287941 | HYDROXYQUINOLINE COMPOUNDS AND METHODS OF USE AS PIGMENT MODIFYING AGENTS - Embodiments disclosed provide pharmaceutical formulations for tyrosinase inhibitors, as well as methods for dermatological treatment of hyperpigmentation disorders. The pharmaceutical formulations comprise tyrosinase inhibitors, each containing a structural core of 8-hydroxyquinoline, and are applied in a suitable carrier as topical treatments for hyperpigmentation. In some embodiments at least one additional dermatologically active compound is present in the pharmaceutical formulation. | 2022-09-15 |
20220287942 | METHOD FOR ENHANCING SCALP ACTIVE DEPOSITION - The present invention is directed to a method of making a personal care composition comprising the following steps: combine a particulate scalp active with an anionic polymer to form a mixture (a); combine the mixture (a) with a cationic polymer having a charge density of 3 to 10 meq/gram to form a mixture (b); combine mixture (b) into a personal care composition base. | 2022-09-15 |
20220287943 | METHOD FOR TREATING KERATIN MATERIAL, COMPRISING THE APPLICATION OF AN ORGANIC C1-C6-ALKOXY-SILANE AND AN AMINO ACID AND/OR AMINO ACID DERIVATIVE - It is an object of the present disclosure to provide a method for treating keratinous material, in particular human hair, wherein on the keratinous material are applied:
| 2022-09-15 |
20220287944 | SILK PERSONAL CARE COMPOSITIONS - This disclosure is in the field of novel surfactant blend of silk fibroin protein fragments and a natural surfactant and personal care compositions and products thereof. | 2022-09-15 |
20220287945 | COMPOSITIONS AND METHODS OF USE THEREOF FOR ANTISEPTIC MOUTH RINSES - In an embodiment, the present disclosure relates to a two-part oral rinse composition having a first rinse portion and a second rinse portion. In some embodiments, the first mouth rinse portion includes sodium chlorite (NaClO | 2022-09-15 |
20220287946 | ANHYDROUS SKIN CARE COMPOSITION COMPRISING RETINOL AND/OR BAKUCHIOL - Anhydrous skin care compositions contain encapsulates, which in turn contain active agents, including retinol and/or bakuchiol. When formulated in a stick form and applied to the skin, the pressure applied to the stick during application deposits the skin care composition onto the skin. During application, some of the encapsulates contained in the composition collapse or rupture, releasing some of the retinol and/or bakuchiol payload onto the skin. As application continues, the encapsulates may break up into smaller particles that retain some of the payload of the active agent(s), which remain on the skin and deliver all or a portion of the retained payload to the skin over time, resulting in “extended release” of active agent(s) into the skin. | 2022-09-15 |
20220287947 | HYDROGEL BASED ON ZINC GLUCONATE AND HYALURONIC ACID ESTERS - Disclosed is a hydrogel containing hyaluronic acid esterified on its free hydroxyls with lipoic acid or with lipoic acid and formic acid, or a pharmaceutically acceptable salt thereof, and zinc gluconate. Also disclosed is a process for the preparation of the hydrogel, compositions containing it, and the use of the hydrogel and the compositions thereof in the pharmaceutical and cosmetic fields or as topical or injectable medical devices. | 2022-09-15 |
20220287948 | FILM-FORMING COMPOSITION - Provided is a film-forming composition directly on the skin by electrostatic spraying, the composition being capable of forming a coating film having excellent skin compatibility, adhesion, followability to motion of the skin, and durability against moisture. A film-forming composition, for forming a coating film composed of fibers directly on the skin by electrostatic spraying, wherein the composition comprises the following components (a), (b) and (c), and the coating film formed from the film-forming composition has an elastic modulus of 1×10 | 2022-09-15 |
20220287949 | SAFE PARTICLES FOR THE INTRODUCTION OF USEFUL CHEMICAL AGENTS IN THE BODY WITH CONTROLLED ACTIVATION - This invention provides particles encapsulating colorant that do not produce functional effects or remove functional effects until they are triggered by contacting with at least one exogenous source. The particles in this invention minimize toxic effects the body of the colorant and the material that interacts with an exogenous source as well as minimize body chemicals from degrading both the colorant and the material that interacts with an exogenous source inside the particle. | 2022-09-15 |
20220287950 | MICROPARTICLE-STRUCTURED THICKENER HAVING IMPROVED SENSATION OF USE - The present invention relates to a microparticle-structured thickener having improved sensation of use. Even when swelling in an aqueous phase, the thickener according to the present invention shows the advantage of retaining the form of particles as well as appearing transparent and being high in stability because the particles disperse homogeneously. | 2022-09-15 |
20220287951 | Ultraviolet Blocking Cosmetic Composition In Chromatic Emulsion State - The present invention relates to an ultraviolet blocking cosmetic composition in a chromatic emulsion state, containing a high quantity of an organic ultraviolet-blocking agent, and a silicone-based surfactant in which polyethylene glycol-added dimethicone and polypropylene glycol are cross-linked, and the cosmetic composition according to the present invention can exhibit a stable chromatic emulsion state even if containing a high quantity of the organic ultraviolet-blocking agent. | 2022-09-15 |
20220287952 | COMPOSITIONS CONTAINING EXOSOMES FROM ANIMAL PLACENTA, METHODS FOR PRODUCING THE SAME AND USES THEREOF - Disclosed are a method for preparing exosomes from bovine placenta, lyophilized powder of the exosomes, as well as a composition containing exosomes from animal placenta and a preparation method and use thereof in anti-wrinkle on skin. | 2022-09-15 |
20220287953 | TOPICAL COSMETIC COMPOSITION, USE OF THE COMPOSITION AND TONIC FOR FACIAL APPLICATION - The present invention is a topical cosmetic composition that provides oiliness reduction and control, as well as pore size reduction, maintenance of the pH and the skin's natural and healthy microbiota. The present invention is within the field of cosmetic science, more precisely it concerns skin care preparations. | 2022-09-15 |
20220287954 | PLANT-DERIVED PROTEOGLYCAN AND APPLICATION THEREOF - The present invention relates to a plant proteoglycan obtained from gum arabic obtained from a trunk or branch of Acacia plant (Acacia Senegal Willdenow or Acacia Seyal Delile), having a weight average molecular weight of 900,000-3,500,000, and having a total aldehyde content of not more than 2.0 μmol equivalent/g. A plant proteoglycan having physiological activity equal to or higher than that of animal proteoglycan can be provided by the present invention. | 2022-09-15 |
20220287955 | COSMETIC FORMULATION - Disclosed is a method of applying a topical skin composition to skin. The composition can include hydrolyzed algin, and | 2022-09-15 |
20220287956 | COMPOSITION CONTAINING CIRSIUM JAPONICUM EXTRACT AS ACTIVE INGREDIENT FOR STIMULATING MELANOGENESIS - The present invention relates to a composition for stimulating melanogenesis, comprising | 2022-09-15 |
20220287957 | COMPOSITIONS AND METHODS FOR USING ALTERNATING ELECTRIC FIELDS TO DISRUPT NANOPARTICLES - Disclosed are methods comprising: administering a drug-loaded nanoparticle to a subject; and exposing a target site of the subject to an alternating electric field for a period of time, the alternating electric field having a frequency and field strength, and wherein the alternating electric field triggers the release of the drug from the drug-loaded nanoparticle at the target site of the subject. Disclosed are methods comprising: administering a drug-loaded nanoparticle to a subject; and exposing a target site of the subject to an alternating electric field for a period of time, the alternating electric field having a frequency and field strength, wherein the alternating electric field triggers the release of the drug from the drug-loaded nanoparticle at the target site of the subject, thereby decreasing non-target site specific release of the drug. Disclosed are methods of treating cancer in a subject comprising administering a drug-loaded nanoparticle to a subject having cancer; and exposing a target site of the subject to an alternating electric field for a period of time, the alternating electric field having a frequency and field strength, wherein the target site comprises a cancer cell; wherein the alternating electric field triggers the release of the drug from the drug-loaded nanoparticle at the target site of the subject; wherein the drug kills the cancer cell. Disclosed are methods of killing cancer cells comprising administering a drug-loaded nanoparticle to a subject; and exposing a target site of the subject to an alternating electric field for a period of time, the alternating electric field having a frequency and field strength, wherein the alternating electric field triggers the release of the drug from the drug-loaded nanoparticle at the target site of the subject, wherein the target site comprises cancer cells, wherein the drug kills the cancer cells. | 2022-09-15 |
20220287958 | DEEP TOPICAL SYSTEMIC NITRIC OXIDE THERAPY APPARATUS AND METHOD - A topical mixture that produces nitric oxide and a method for using the topical mixture to increase the vasodilation of a bloodstream via transdermal absorption of the nitric oxide. The nitric oxide can then affect subcutaneous tissues. The systemic vasodilation of a mammal may be increased via a topical application of an appropriate nitric oxide producing substance. | 2022-09-15 |
20220287959 | IMPLANTABLE CAPSULE - Implantable capsule comprising a cell receiving portion ( | 2022-09-15 |
20220287960 | SUSTAINED RELEASE ESTROGEN VAGINAL RING PESSARY FOR TREATMENT OF ATROPHY, CYSTITIS AND UTEROVAGINAL PROLAPSE - The present invention relates to devices and methods for treating prolapsed pelvic organ, cystitis and Atrophy in women. Particularly, the invention relates to drug loaded vaginal support devices and methods wherein the device is inserted in vagina to support as well as release the drug. Specifically the invention relates to a Vaginal Ring Pessary comprising Estrogen in Silicone rubber polymer matrix, which releases drug over a prolonged period of about 180 days. Additionally the invention relates to the method of fabrication of the device and its use in treatment of vaginal atrophy, cystitis and uterovaginal prolapse. | 2022-09-15 |
20220287961 | COMPOSITIONS AND METHODS FOR TREATMENT OF OCULAR DISEASES - The present disclosure relates to compositions and methods for treating ocular diseases with antibiotics. In particular, the disclosure relates to non-blurring, antibiotic-containing hydrogel compositions that have an extended contact time on the eye and do not interfere with wound healing. | 2022-09-15 |
20220287962 | DEVICES AND METHODS FOR TREATING EAR PAIN - The present invention relates generally to a methods and apparatuses for treating ear pain and clearing excess fluid from Eustachian tubes. | 2022-09-15 |
20220287963 | Hydrocortisone Acetate Suppository Formulation For Treatment Of Disease - The present invention relates, in various embodiments, to formulations comprising hydrocortisone and silicon dioxide. In additional embodiments, the invention relates to suppositories comprising hydrocortisone and silicon dioxide. The formulations of the present invention are useful for administration to patients who have gastrointestinal diseases and disorders such as, for example, inflammatory bowel disease. | 2022-09-15 |
20220287964 | TOPICAL FORMULATIONS COMPRISING CANNABIDIOL, METHOD OF PREP ARING THE COMPOSITION AND USE THEREOF - A hydroalcoholic gel composition is disclosed for alleviating symptoms of psoriasis or arthritis, such as pain resulting from arthritic diseases and/or psoriatric arthritis and/or neurological pain, such as pain resulting from sclerosis, e.g. multiple sclerosis in a subject. Such a composition may comprise, inter alia, 0.1-20% cannabidiol, a skin penetration enhancer, ethanol, and one or more thickeners and/or gelling agents. | 2022-09-15 |
20220287965 | OLEOGELS AND METHODS RELATING THERETO - The presently disclosed subject matter relates generally to oleogels, particularly to oleogels that can be used for delivering active ingredients such as probiotics. Also described herein are methods for preparing and using such delivery systems. | 2022-09-15 |
20220287966 | Stable Liquid Lipid Nanoparticle Formulations - The present invention provides, among other things, a liquid lipid nanoparticle (LNP) formulation encapsulating mRNA encoding a peptide or polypeptide, that is resistant to aggregation and to mRNA degradation following multiple rounds of freezing at −20° C. and rethawing. | 2022-09-15 |
20220287967 | EXOSOME MIMICKING NANOVESICLES MAKING AND BIOLOGICAL USE - This disclosure provides an exosome mimicking nanovesicle (EMN) comprising cell-derived plasma membrane or lipid rafts and substantially devoid of native exosomes. The EMNs can be derived from a differentiated cell or a stem cell. They are useful to carry a variety of cargo, e.g., a secretome, or exogenous agent selected from a polynucleotide, a peptide, a protein, an antibody fragment, a chemical, or a therapeutic agent. They are useful for the treatment of a variety of diseases and disorders. | 2022-09-15 |
20220287968 | LIPID VESICLE-MEDIATED DELIVERY TO CELLS - The invention concerns a lipid vesicle (LV), such as a liposome, that has been loaded with a cargo molecule covalently or non-covalently coupled to a cell penetrating polypeptide (resulting in a “binding complex”), and the binding complex or cargo molecule has been internalized by, or is associated with, the LV. Another aspect of the invention concerns a method for loading an LV with a cargo molecule, comprising contacting the LV with the binding complex, wherein the binding complex or cargo molecule becomes internalized by, or associated with, the LV. Another aspect of the invention concerns a method for delivering a cargo molecule into a cell in vitro or in vivo, comprising administering a loaded LV to the cell in vitro or in vivo, wherein the loaded LV is internalized into the cell, and wherein the loaded LV comprises the cargo molecule and a cell penetrating polypeptide. | 2022-09-15 |
20220287969 | MULTILAMELLAR RNA NANOPARTICLES - The present disclosure provides a nanoparticle comprising a positively-charged surface and an interior comprising (i) a core and (ii) at least two nucleic acid layers, wherein each nucleic acid layer is positioned between a cationic lipid bilayer. Methods of making such nanoparticles are further provided herein. Additionally, related cells, populations of cells, pharmaceutical compositions comprising the presently disclosed nanoparticles are provided. Methods of increasing an immune response against a tumor in a subject, methods of delivering RNA molecules to an intra-tumoral microenvironment, lymph node, and/or a reticuloendothelial organ in a subject, and methods of treating a subject with a disease are furthermore provided. | 2022-09-15 |
20220287970 | COMPOSITION FOR INHIBITING SAPONIN-INDUCED HEMOLYSIS, CONTAINING CATIONIC LIPOSOME - A cationic liposome having the effect of inhibition of red blood cell hemolysis induced by saponin is disclosed. More particularly, a composition for inhibiting red blood cell hemolysis by saponin comprising a cationic liposome containing an unsaturated lipid, a composition for immunity enhancement and a composition for drug delivery comprising the composition for inhibiting red blood cell hemolysis by saponin, and a drug delivery carrier and a drug-carrier complex comprising a cationic liposome containing an unsaturated lipid are disclosed. | 2022-09-15 |
20220287971 | Method for Preparing Transmembrane pH-Gradient Vesicles - A method for preparing transmembrane pH-gradient vesicles is provided. This method includes the following steps: a) preparing vesicles made from at least one matrix substance in an aqueous medium having an osmolarity of not more than 200 mOsm/l, wherein the matrix substance is chosen from the group consisting of amphiphilic lipids and amphiphilic block copolymers, b) transferring the vesicles into a basic or acidic buffer having an osmolarity being at least 200 mOsm/l higher than the osmolarity of the aqueous medium of step a) to apply an osmotic shock to the vesicles and to obtain buffer-filled vesicles and c) diluting a mixture of the aqueous medium and the basic or acidic buffer containing the buffer-filled vesicles by adding a neutralizing solution to obtain transmembrane pH-gradient vesicles suspended in a suspension buffer, wherein the suspension buffer differs from the basic or acidic buffer in pH value. | 2022-09-15 |
20220287972 | TREATMENT APPROACH BY TARGETED DELIVERY OF BIOACTIVE MOLECULES - A method of treating a bacterial infection in a subject includes administering at least a first finely divided (particulate) material, which may have at least a second material, the first material is not bioresorbable or very slowly bioresorable and the second material or materials are bioresorbable at a higher rate than the first material, allowing a certain period of time to pass in order to provide for the first particulate material to be exposed to the body and/or second material or materials to be wholly or partly absorbed by the body of the subject, and administering one or more pharmaceutically active compounds. The first material is optionally pre-loaded or soaked with one or more pharmaceutically active compounds, and the second material is optionally pre-loaded or soaked with one or more pharmaceutically active compounds. The pharmaceutically active compound is a compound capable of treating or ameliorating a bacterial infection. | 2022-09-15 |
20220287973 | ORODISPERSIBLE POWDER COMPOSITION COMPRISING A TRIPTAN - An orodispersible powder composition including a triptan and a ternary synergistic combination of sodium citrate, citric acid and sucralose, as well as a stick pack including such a powder composition, and its use in the treatment of migraine. | 2022-09-15 |
20220287974 | Co-Processed Lubricant:MCG for Tablets - The present invention is directed to a co-processed lubricant excipient which can be used to manufacture tablets, and pharmaceutical compositions containing the same. | 2022-09-15 |
20220287975 | MODIFIED RELEASE COMPOSITIONS OF NAFAMOSTAT AND METHODS OF USING SAME - Aspects of the present disclosure include a composition of nafamostat or a pharmaceutically acceptable salt thereof that provides for controlled release of nafamostat or pharmaceutically acceptable salt thereof to a subject for an extended period of time. Compositions according to certain embodiments include a plurality of controlled release beads where each bead includes a core, an active agent layer having nafamostat or a pharmaceutically acceptable salt thereof and a controlled release layer having one or more polymers formulated in an amount sufficient to provide for controlled release of the nafamostat or pharmaceutically acceptable salt thereof. Methods for administering (e.g., orally) the controlled release nafamostat compositions to a subject are also described. | 2022-09-15 |
20220287976 | AMMONIA AS A PROCESSING AID FOR SPRAYED SOLID DISPERSIONS - Ammonia is used as a processing aid in a method for forming a sprayed solid dispersion comprising an active agent, wherein the active agent, in a free acid form, has a pKa≤7 and a solubility≤40 mg/mL in the spray solvent. Ammonia is subsequently removed from the sprayed solid dispersion. Sprayed solid dispersions formed by the disclosed method are also disclosed. | 2022-09-15 |
20220287977 | ORAL PRODUCTS AND METHODS OF MANUFACTURE - Compositions configured for oral use, the compositions including at least one active ingredient selected from caffeine, taurine, GABA, theanine, tryptophan, vitamin B6, vitamin B12, vitamin C, lemon balm extract, ginseng, citicoline, sunflower lecithin, cannabinoids, cannabimimetics, terpenes, or combinations thereof, are provided. The compositions include one or more fillers, including a sugar alcohol, and optionally, a lipid or binder. The compositions may be in chewable, tablet, pastille, or meltable forms. Further provided are methods of preparing such compositions. | 2022-09-15 |
20220287978 | PHARMACEUTICAL COMPOSITIONS - The present invention relates to solid oral fixed dose compositions of metformin, atorvastatin, and valsartan, or their pharmaceutically acceptable salts, processes for the preparation thereof, and the use of the composition to treat certain diseases. | 2022-09-15 |
20220287979 | METHOD OF PREPARING A SOLID DOSAGE FORM AND A LUBRICANT - The present invention is related to a method of preparing a solid dosage form, comprising the steps of: a. preparing a lubricant consisting of at least one polyunsaturated fatty acid salt; b. adding the lubricant and ingredients for the solid dosage form to a mixer; c. optionally carrying out one or more of the following steps: granulation, drying and sizing, d. blending the contents of the mixer; and e. compressing or slugging the blended contents to produce a solid dosage form. Solid dosage forms prepared according to this method and the use of PUFA salts as lubricant in tableting applications for compression of solid components are further comprised by the present invention. | 2022-09-15 |
20220287980 | PHARMACEUTICAL COMPOSITION AND USES THEREOF - The present invention relates to pharmaceutical compositions comprising fixed dose combinations of a DPP-4 inhibitor drug and/or a SGLT-2 inhibitor drug, and metformin XR, processes for the preparation thereof, and their use to treat certain diseases. | 2022-09-15 |
20220287981 | ADHESIVE DRUG DELIVERY MICROPARTICLES AND A PRODUCT COMPRISING THEREOF - There is provided herein a microparticle for the administration of a pharmaceutical composition at the upper gastrointestinal tract comprising: a core comprising at least one pharmaceutical composition; at least one excipient a first coating layer comprising a bioadhesive material; optionally, a channel forming agent; a film forming polymer; and a cross-linker wherein said cross-linker interacts with said film forming polymer upon exposure to an aqueous environment. | 2022-09-15 |
20220287982 | EMBRYONIC MICROSPHERE PREPARATION METHOD AND PREPARATION MECHANISM, MICROSPHERE PREPARATION METHOD AND PREPARATION APPARATUS - The invention discloses a method for preparing embryonic microspheres, a preparation mechanism, a method for preparing microspheres and a device for preparing the microspheres. The method for preparing the microspheres comprises delivering a microsphere-forming solution to a porous membrane located in a receiving liquid through a liquid transport member, to form embryonic microspheres; delivering embryo microspheres separated from the porous membrane along a channel filled with the receiving liquid, hardening the embryo microspheres to form microspheres; and collecting the microspheres. Wherein the flow rate of output liquid from the liquid transport member is controllable, so that an amount of output microsphere-forming solution per unit time is directly controlled, thereby regulating the particle size and uniformity of the generated microspheres. The present method improves the yield of the microspheres by eliminating variations in the surface tension distribution across the embryonic microspheres caused by mixing air bubbles into the embryo microspheres. | 2022-09-15 |
20220287983 | BRANCHED POLY(-AMINO ESTERS) FOR THE DELIVERY OF NUCLEIC ACIDS - The present disclosure provides branched poly(β-amino esters) (PBAEs) of Formula (I) made by reacting primary amines with diacrylates. Further provided herein are compositions comprising the polymers of Formula (I), and methods of using the compositions and polymers as described herein for the treatment of disease. | 2022-09-15 |
20220287984 | COMPOSITIONS AND METHODS FOR REMOVING BIO-SYNTHETIC NANO-PARTICLES FROM BODILY FLUIDS - Bait and capture methods and compositions for removing bio-synthetic nano-particles from body fluids. Bio-synthetic nano-particles are baited with one-half of a bait and capture complex and lyophilized. The baited bio-synthetic nano-particle is reconstituted and administered to a subject for diagnostic or therapeutic purposes. To remove the bio-synthetic nano-particle from the body, the body fluid containing the baited bio-synthetic nano-article is contacted with the capture portion of the bait and capture complex. The body fluid from which the bio-synthetic nano-particles have been removed may be returned to the subject. | 2022-09-15 |
20220287985 | ORGANIC NANOPARTICLE PRODUCTION METHOD AND ORGANIC NANOPARTICLES - Provided is an organic nanoparticle production method comprising a step in which a mixture of beads having an average particle size at least 0.15 mm and no more than a value (mm) calculated by the formula 1.07−0.11×[outer peripheral speed of the stirring rotor (m/sec)] and a slurry containing organic particles is stirred by a stirring rotor rotating at an outer peripheral speed of 7 m/sec or less in a vessel of a wet bead mill. | 2022-09-15 |
20220287986 | Intraarterial (IA) Application of Low Dose of Ethyl Alcohol Enables Blood-Brain Barrier (BBB) Impermeable Therapeutics Brain Entry - A method of inducing blood-brain barrier (BBB) opening of for delivery of a non-BBB permeable substance to a subject includes the steps of: administering an ethyl alcohol at 0.015%-5% v/v into a blood stream of the subject via intra-arterial injection, intracardiac injection, or intra-arterial injection guided by ultrasound, wherein said ethyl alcohol reaches a brain of the subject to induce opening of blood-brain barrier so that the non-BBB permeable substance is capable of penetrating the blood-brain barrier to reach the brain of the subject. The non-BBB substance includes a therapeutic agent, a diagnostic agent, or a prophylactic agent. The use of low concentration of ethyl alcohol can induce a temporary BBB opening within 240 minutes after administration so that the non-BBB substance can be deliver to the brain during the time frame of BBB opening. Since ethyl alcohol is water soluble, the non-BBB substance can also be administered concurrently. | 2022-09-15 |
20220287987 | MYO-INOSITOL AND THE PREVENTION OF PPROM - The present invention relates generally to the field of compositions comprising myo-inositol for use in the prevention of a preterm-onset pre-labour rupture of membranes (PPROM) and disorders and/or conditions linked thereto. The composition may be a nutritional composition, for example a maternal nutrition composition. The composition may be specifically designed to provide optimized nutrition to a woman desiring to get pregnant or to a pregnant woman. | 2022-09-15 |
20220287988 | MYO-INOSITOL AND THE PREVENTION OF PRETERM BIRTH - The present invention relates generally to the field of compositions comprising myo-inositol for use in the prevention of preterm birth and/or of conditions linked to preterm delivery in a female subject and/or in the offspring. The composition may be a nutritional composition, for example a maternal nutrition composition. The composition may be specifically designed to provide optimized nutrition to a woman desiring to get pregnant or to a pregnant woman. | 2022-09-15 |
20220287989 | USE OF TAPINAROF FOR THE TREATMENT OF ATOPIC DERMATITIS - Topical compositions and methods for using topical compositions comprising tapinarof to treat mild to moderate atopic dermatitis are described herein. Also described are clinical endpoints for treatment of subjects diagnosed with mild to moderate atopic dermatitis, wherein about 5% to about 35% of body surface area was affected, and Investigator Global Assessment (IGA) score was greater than or equal to 3. | 2022-09-15 |
20220287990 | TOPICAL JAK INHIBITOR COMBINATION COMPOSITIONS FOR TREATMENT OF INFLAMMATORY SKIN CONDITIONS - Provided herein is a topical combination composition and a method of treatment of an inflammatory skin condition by administration of said composition comprising at least one Janus kinase inhibitor (JAK inhibitor) and at least one additional active agent elected from benzoyl peroxide (BPO), at least one retinoid, tapinarof, at least one antibiotic, at least one antiandrogen, at least one acaricide and combinations thereof and a carrier suitable for topical administration. The JAK inhibitor and the at least one additional active agent exhibit an additive or synergistic effect, allowing to reduce the amounts of active agents in the composition. | 2022-09-15 |
20220287991 | USE OF DIAMINOGUANIDINE DERIVATIVE AND FEED COMPOSITION THEREOF IN PREPARATION OF VETERINARY DRUG - Disclosed is a use of a diaminoguanidine derivative and a feed composition thereof in the preparation of a veterinary drug. Particularly, disclosed is a use of a diaminoguanidine derivative having a structure of formula (I), or a stereoisomer, geometric isomer, tautomer, solvate, pharmaceutically acceptable salt thereof, or a prodrug thereof, in the preparation of an animal drug for preventing, managing, treating, or alleviating a disease resulting from bacterial infection, wherein R is NO | 2022-09-15 |
20220287992 | COMPOSITIONS COMPRISING ENZYME-CLEAVABLE PRODRUGS AND CONTROLLED RELEASE NAFAMOSTAT AND METHODS OF USE THEREOF - Aspects of the present disclosure include pharmaceutical compositions, and their methods of use, where the pharmaceutical compositions include an active agent prodrug that provides enzymatically-controlled release of an active agent, and controlled release nafamostat or a pharmaceutically acceptable salt thereof. | 2022-09-15 |
20220287993 | PHARMACEUTICAL COMPOSITION COMPRISING HDAC INHIBITOR AND ANTI-PD1 ANTIBODY OR ANTI PD-L1 ANTIBODY - The present invention relates to a method for killing cancer cells by using a combination of an HDAC inhibitor and an anti-PD1 antibody or an anti PD-L1 antibody. The present invention can have an effective influence on: extending the survival of animals with cancer, tumors, tumor-related disorders and neoplastic diseases; inhibiting the growth of proliferative cells associated with neoplasms; or neoplastic degeneration. | 2022-09-15 |
20220287994 | N,N-BIS-2-MERCAPTOETHYL ISOPHTHALAMIDE FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES - According to the invention there is provided N,N-bis-2-mercaptoethyl isophthalamide, or a pharmaceutically acceptable salt or derivative thereof, for use in the therapeutic treatment of a neurodegenerative disorder, such as Alzheimer's disease, Parkinson's disease, Huntington's disease and/or amyotrophic lateral sclerosis. | 2022-09-15 |
20220287995 | COMPOSITIONS AND METHODS FOR INHIBITING BACTERIAL VIRULENCE AND FLIM-BASED DEVICE AND METHOD FOR ANTIBIOTIC SUSCEPTIBILITY TESTING - Compositions and methods for inhibiting bacterial virulence, as well as methods and materials for use in rapid assessment of antibiotic susceptibility are described. A method for inhibiting bacterial virulence comprises exposing a site containing or suspected of containing virulent bacteria to a carbon source, wherein the carbon source produces a low g value. Examples of such carbon sources include pyruvate, citrate, oxaloacetate, malate, and fumarate. The carbon source can be applied to a surface or administered to a subject. A device for testing antibiotic susceptibility of bacteria comprises a fluorescence lifetime imaging microscopy (FLIM) apparatus that emits an excitation pulse of light directed at a receiving surface; a detector that collects time-correlated fluorescence emitted from individual bacteria immobilized on the receiving surface; an analyzer that generates a FLIM-phasor profile; and an analyzer that correlates the FLIM-phasor profile to the status of the antibiotic susceptibility of the bacteria. | 2022-09-15 |
20220287996 | METHODS AND COMPOSITIONS FOR TREATING EDEMA REFRACTORY TO ORAL DIURETICS - The present invention features methods and compositions for the intranasal, sublingual, and subcutaneous administration of bumetanide for the treatment of subjects suffering from edema refractory to oral diuretics. | 2022-09-15 |
20220287997 | Effects of Heparin on Topical Use of Plasters Containing a Non-Steroidal Anti-Inflammatory Drug - The present invention provides for a method of improving the release of non-steroidal anti-inflammatory drugs (NSAIDs) from a plaster or bandage comprising an adhesive layer with a pharmaceutically acceptable NSAID together with heparin or a heparinoid. The invention also provides for methods of reducing muscle hyperalgesia in subjects without spontaneous pain. | 2022-09-15 |
20220287998 | USE OF C3aR IN PREPARING DRUG FOR PREVENTING OR TREATING POLYCYSTIC KIDNEY DISEASE - The disclosure provides a use of C3aR in preparing drugs for preventing or treating polycystic kidney disease, belonging to the technical field of medicines. The disclosure discovers that C3aR inhibitor can down-regulate or reduce the C3aR level by inhibiting proliferation of cyst epithelial cells, blocking chemotaxis of C3a-C3aR on macrophages, inhibiting the interaction between C3a and C3aR, and expressing the p-ERK, p-P65 proteins, and then prevent cyst growth, improve the inflammatory state, thus treating polycystic kidney disease. The C3aR inhibitor can be used for the development of novel lead compounds for preventing or treating autosomal dominant polycystic kidney disease, and also can be used for preparing drugs for preventing or treating polycystic kidney disease. | 2022-09-15 |
20220287999 | TREATMENT OF DIABETES - Disclosed herein is the use of a HIF-1α inhibitor for preventing, delaying or treating diabetes mellitus in a subject. The subject is susceptible to, or has diabetes mellitus and has elevated non-fasting blood glucose, and/or elevated fasting blood glucose, and/or impaired glucose tolerance and/or elevated hemoglobin A1c levels. In particular, the present disclosure relates to the use of a HIF-1α inhibitor, wherein the HIF-1α inhibitor is administered to the subject, thereby maintaining or providing increased non-fasting plasma insulin levels in said subject. | 2022-09-15 |
20220288000 | CHEWABLE FORMULATIONS - The invention relates to tyrosine hydroxylase inhibitor compositions and methods of preparing and administering thereof. Specifically, the invention relates to an oral chewable formulation of a tyrosine hydroxylase inhibitor, particularly α-methyl-DL-tyrosine. | 2022-09-15 |
20220288001 | CREATINE FOR IMMUNOTHERAPY - As disclosed herein, we have discovered that creatine is a critical molecule buffering ATP levels in cancer-targeting CD8 T cells through maintaining a readily available high-energy phosphate reservoir. Building upon this discovery, we have designed a number of methods for modulating energy metabolism in a population of tumor-infiltrating CD8 T cells, methods that can be adapted for use in therapeutic regimens for the treatment of cancer. Illustrative embodiments of the invention include methods for enhancing tumor-infiltrating CD8 T cells ability to mount and sustain a response to tumor cells comprising increasing the concentrations of creatine available for tumor-infiltrating CD8 T cells energy metabolism, thereby enhancing the ability of the tumor-infiltrating CD8 T cells to mount and sustain a response to the tumor cells. | 2022-09-15 |
20220288002 | Composition comprising EPA, MA and leucine for improving muscle function - The invention relates to compositions comprising EPA, MA and leucine for prevention and/or treatment of a disease or condition involving muscle decline or for improving muscle function. | 2022-09-15 |
20220288003 | COMPOSITIONS AND METHODS FOR TREATING RETINOPATHY - The present invention provides methods, compositions, and kits for treating retinopathy, including diabetic retinopathy and macular degeneration, in a subject in need. | 2022-09-15 |
20220288004 | TREATMENT AND PREVENTION OF AGING RELATED-DISEASE AND/OR AGING BY THE INHIBITION OF SPHINGOLIPIDS - The present invention relates to an inhibitor of sphingolipids for use in the treatment or prevention of an aging related-disease and/or aging. | 2022-09-15 |
20220288005 | SYNTHESIS OF PRO-RESOLVING ANALOGS AND COMPOSITIONS THEREFOR - This disclosure relates to methods of synthesizing certain lipoxin analogs (e.g., lipoxin mimetics, etc.) and pharmaceutical compositions comprising these pro-resolving compounds. Methods of administering the lipoxin mimetics (e.g., lipoxin A4 mimetics, lipoxin B4 mimetics, etc.) to patients in need thereof are also provided. | 2022-09-15 |
20220288006 | GLYCERYL TRIS (BETA-HYDROXYBUTYRATE) AND NEURONAL TRANSIENT ISCHEMIC ATTACKS - A method of use of Gylceryl Tris (Beta-hydroxybutyrate) in the minimization, reduction, or prevention of neuronal deficit and/or neuronal cell death with respect to follow-on neuronal transient ischemic attacks (NTIAs) in subjects who have had (or in subjects exhibiting symptomology of having had) at least one prior NTIA. | 2022-09-15 |
20220288007 | Platinum Complex Anti-Neoplastic Agents Comprising a Cannabinoid Ligand - This disclosure provides platinum complex anti-neoplastic agents that comprise at least one cannabinoid ligand as either a leaving ligand or an axial ligand. After the agent enters the cell, the cannabinoid ligand is released as a cannabinoid, where the cannabinoid can then provide additional therapeutic benefits. | 2022-09-15 |
20220288008 | JUICE BEVERAGE FOR PREVENTION AND TREATMENT OF RENAL STONES - Described are edible citrate-rich compositions, including natural juice beverages fortified with natural occurring citrates and synthesized citrate sources that will aid in treatment and prevention of urolithiasis and other urinary tract disorders. Urolithiasis encompasses conditions in which stones are formed or reside in the urinary system and includes nephrolithiasis (stones in the kidneys), ureterolithiasis (stones in the ureter) and cystolithiasis (stones in the bladder) | 2022-09-15 |
20220288009 | CABAZITAXEL LIQUID FORMULATIONS - The present invention relates to the stable liquid pharmaceutical composition comprising (a) cabazitaxel or a pharmaceutically acceptable salt or solvate thereof, (b) one or more solubilizers selected from the group consisting of soya phosphatidyl choline, polyethylene glycol and glycocholic acid, (c) a solvent and (d) a co-solvent, wherein the pharmaceutical composition is substantially free of (i) polysorbates and (ii) stabilizers selected from the group consisting of preservatives, antioxidants and chelating agents and the process for preparation thereof, and the methods of using the stable liquid pharmaceutical composition of cabazitaxel for the treatment of patients with hormone refractory metastatic prostate cancer previously treated with a docetaxel containing treatment regimen. | 2022-09-15 |
20220288010 | METHODS FOR REDUCING REWARDING EFFECTS OF MORPHINE WITHOUT AFFECTING ITS ANALGESIC EFFECTS - The present disclosure provides methods and compositions for inhibiting monoacylglycerol lipase (MAGL) in order to attenuate the rewarding effects of and delay tolerance to the analgesic properties of opioids such as morphine without reducing their analgesic effects. | 2022-09-15 |
20220288011 | METHODS OF INDUCING ANESTHESIA - The present invention provides methods for determining the selectivity of an anesthetic for an anesthetic-sensitive receptor by determining the molar water solubility of the anesthetic. The invention further provides methods for modulating the selectivity of an anesthetic for an anesthetic-sensitive receptor by altering or modifying the anesthetic to have higher or lower water solubility. The invention further provides methods of inducing anesthesia in a subject by administering via the respiratory pathways (e.g., via inhalational or pulmonary delivery) an effective amount of an anesthetic compound identified according to the present methods. | 2022-09-15 |
20220288012 | PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF - The present invention relates to methods for treating or preventing chronic kidney disease and cardiovascular disease in patients with chronic kidney disease comprising administering empagliflozin to the patient. | 2022-09-15 |
20220288013 | 1,8-CINEOL COATED IMPLANTS - Apparatuses, devices, compositions, and methods to ameliorate undesired side effects or outcomes, such as fibrosis due to surgical implants, wounds, or other bodily injury. In particular, described are apparatuses, devices, and compositions containing inhibitors of Wnt11 as well as methods of making and using them. These apparatuses, devices, compositions, and methods may be especially useful for preventing, reducing or treating unwanted fibrosis, such as that resulting from a biomedical implant implanted in an individual. | 2022-09-15 |
20220288014 | ORAL FORMULATIONS OF CANNABIS EXTRACTS AND METHODS OF MAKING SAME - The current application relates to a composition comprising a | 2022-09-15 |
20220288015 | CANNABINOID ACID ESTER COMPOSITIONS AND USES THEREOF - The present disclosure provides pharmaceutical compositions including a cannabinoid acid ester compound alone or in combination with one or more additional cannabinoid compounds. In some embodiments, the cannabinoid acid ester compound is a tetrahydrocannabinolic acid (THCA) ester. In some embodiments, the cannabinoid acid ester compound is a cannabigerolic (CBGA) acid ester. In some embodiments, the cannabinoid acid ester compound is a cannabinolic (CBNA) acid ester. A variety of therapeutic applications in which the cannabinoid acid ester compounds and pharmaceutical compositions find use are also provided, including combination therapies using cannabinoid acid ester compounds and one or more additional therapeutic agents. | 2022-09-15 |